Real-life Ecological Momentary Assessment of Lived Burden in Hereditary AngioEdema (REAL-HAE)
The aim of this study is to conduct an in-depth analysis of the Burden of Disease (BoD) perceived by patients with Hereditary Angioedema (HAE), through daily prospective observations based on Ecological Momentary Assessment (EMA) via digital surveys and standardised questionnaires.
Participants will answer online survey questions about their perceived burden of disease for 8 consecutive weeks. The main hypothesis is that daily prospective observation (EMA) will reveal a higher and more fluctuating burden of disease compared to traditional retrospective scales, providing a more accurate representation of the impact of HAE on patients' daily lives.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent attacks of non-pruritic edema, localized at the subcutaneous, submucosal, and visceral levels. These attacks, caused by a temporary and localized increase in vascular permeability mediated by bradykinin, can affect the skin, gastrointestinal tract, face, genitals, and upper airways, resulting in a risk of asphyxiation. The most common forms of HAE are Type 1 (85-90%), caused by a quantitative deficiency of C1-inhibitor (HAE-C1INH-Type1), and Type 2 (10-15%), due to a qualitative dysfunction of the same (HAE-C1INH-Type2). In Italy, the overall prevalence is estimated at approximately 1:65,000.
HAE attacks occur unpredictably, with an average frequency that is highly heterogeneous between subjects, ranging on average from 1 to 26 episodes per year; some severe cases can reach 100 attacks per year. These manifestations have an average duration of about 2-5 days and are often debilitating, significantly compromising quality of life (QoL) and the subject's functional abilities. The impact of the disease is not limited to the presence, duration, or frequency of attacks but persists during intercritical periods, often accompanied by anticipatory anxiety and a constant sense of vulnerability, which can lead to a state of hypervigilance.
Numerous studies describe the Burden of Disease (BoD) as multidimensional. The impact on QoL concerns physical, psychological, social, and professional dimensions. From a psychological and emotional perspective, many HAE patients report high levels of stress, anxiety, and depressive symptoms, often linked to the unpredictability of attacks and the perception of poor control over their condition. Furthermore, despite therapeutic progress, the potential risk of fatal laryngeal edema remains a significant source of concern for many patients, contributing to a persistent emotional burden.
At the professional level, a reduction in productivity is observed due to both absenteeism and presenteeism, with European studies documenting an average of up to 20 days lost per year between school and work. Finally, on a social level, some patients report experiences of stigmatization or discrimination, with a negative impact on relational well-being and social integration.
Until now, BoD in HAE has been assessed primarily through retrospective questionnaires and standardized measures administered at single time points, such as the Angioedema Quality of Life (AE-QoL), the Angioedema Activity Score (AAS), or the Work Productivity and Activity Impairment Questionnaire: General Health (WPAI:GH). While validated and widely used, these instruments present several methodological limitations. In particular, they rely on subjective estimates reported within more or less broad time windows (e.g., the last two weeks or the previous month) and are therefore susceptible to recall bias, the mnemonic distortion in the reconstruction of past experiences. Moreover, these tools are developed to provide a static snapshot of subjective BoD, which may fail to capture the dynamic trends and the intra- and inter-individual fluctuations typical of the HAE experience, especially concerning emotional, social, or symptomatic events occurring in daily life.
In light of these considerations, this study will apply the Ecological Momentary Assessment (EMA) method. This is an innovative observational data collection method that allows for the repeated collection of self-report data over time through brief questionnaires sent to the participant's smartphone at specific and/or random moments of the day. EMAs are based on simple, intuitive, and quick items, similar to those found in traditional psychometric tools, but administered multiple times over time and within the context of the patient's real life.
This approach offers a twofold advantage:
- It reduces recall bias, as the person is prompted to respond in real-time or in close temporal proximity to the experience.
- It allows for the collection of data with high ecological validity, meaning data that is relevant to the subject's behavior and experience in their natural environment.
This allows for a more precise exploration of the characteristics that constitute BoD in HAE and, consequently, the daily impact of the disease. The present protocol aims to analyze in depth the Burden of Disease (BoD) perceived by HAE patients through daily and prospective observation based on EMAs and standardized scales.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Milan, Italy, 20138
- Recruiting
- Istituti Clinici Scientifici Maugeri, Milan, Milan 20138
-
Contact:
- Francesca Perego, MD, PhD
- Phone Number: +39 0250725239
- Email: francesca.perego@icsmaugeri.it
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Confirmed diagnosis of Type 1 or Type 2 hereditary angioedema;
- Age ≥ 18 years;
- Ability to understand instructions and provide informed consent;
- Ownership and proficiency in using a personal smartphone compatible with the m-Path application (Android or iOS);
- Willingness to participate in the study for the entire duration of the observation period (8 weeks).
Exclusion Criteria:
- Diagnosis of acquired angioedema or other forms of angioedema unrelated to C1-inhibitor deficiency;
- Severe cognitive or psychiatric disorders that compromise the ability to complete the questionnaires independently;
- Age < 18 years;
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Emotional Burden via Ecological Momentary Assessment (EMA)
Time Frame: Every other day for 8 weeks
|
Evaluation of emotional states (anxiety, mood, stress, and fear of attacks) through a Visual Analogue Scale (VAS).
Each item is scored on a range from 0 to 100, where 0 indicates "no emotional impact" and 100 indicates "maximum emotional distress.
|
Every other day for 8 weeks
|
|
Socio-occupational Impairment via Ecological Momentary Assessment (EMA)
Time Frame: Every other day for 8 weeks
|
Assessment of the impact of Hereditary Angioedema (HAE) on daily, social, and professional activities.
Measured via a scale ranging from 1 to 10, where 1 indicates "no impairment" and 10 indicates "maximum perceived impairment"
|
Every other day for 8 weeks
|
|
Disease Activity
Time Frame: AAS is collected every other day for 8 weeks
|
Assessment of the physical burden using the Angioedema Activity Score (AAS): A daily symptom diary, total score from 0 to 15.
|
AAS is collected every other day for 8 weeks
|
|
Angioedema Quality of Life
Time Frame: After 4 weeks and at the end of the 8 weeks
|
Assessment of quality of life impairment using the AE-QoL questionnaire.
The total score ranges from 17 to 85, where higher scores indicate greater impairment.
|
After 4 weeks and at the end of the 8 weeks
|
|
Disease Control
Time Frame: After 4 weeks and at the end of the 8 weeks.
|
Assessment of disease control using the AECT.
The total score ranges from 0 to 16, where lower scores indicate poorer disease control.
|
After 4 weeks and at the end of the 8 weeks.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Anxiety and Depressive Symptoms
Time Frame: Every other week for 8 weeks
|
Measured via the Patient Health Questionnaire-4 (PHQ-4), a 4-item screening scale for anxiety and depression.
Each item is scored from 0 to 3. The total score ranges from 0 to 12, where higher scores indicate more severe symptoms of anxiety and depression.
|
Every other week for 8 weeks
|
|
Work Productivity and Activity Impairment (WPAI:GH)
Time Frame: Once a week for 8 weeks
|
The WPAI:GH measures the impact of health problems on work productivity and daily activities.
It yields four scores: absenteeism, presenteeism, overall work impairment, and activity impairment.
Results are expressed as percentages (0-100%), where higher percentages indicate greater impairment.
|
Once a week for 8 weeks
|
|
Within-person Variability of Emotional States (EMA)
Time Frame: Every other day for 8 weeks
|
Calculated as the standard deviation or Mean Successive Difference (MSSD) of the daily emotional VAS scores (0-100) collected via EMA over the 8-week period.
This measures the "fluctuations" of the patient's emotional state.
|
Every other day for 8 weeks
|
|
Difference in Burden of Disease between LTP and ODT groups
Time Frame: 8 weeks
|
Comparison of the mean Burden of Disease (BoD) scores across all dimensions (physical, emotional, socio-occupational) between patients receiving Long-Term Prophylaxis (LTP) and those receiving On-Demand Treatment (ODT).
|
8 weeks
|
|
Correlation between EMA scores and Traditional Questionnaires
Time Frame: 8 weeks
|
Comparison between the real-time daily scores (EMA) and the retrospective scores (AE-QoL, WPAI:GH, PHQ-4) to measure the difference in patient perception of disease burden.
|
8 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Hereditary Complement Deficiency Diseases
- Primary Immunodeficiency Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Genetic Diseases, Inborn
- Immune System Diseases
- Hypersensitivity, Immediate
- Hypersensitivity
- Immunologic Deficiency Syndromes
- Skin Diseases
- Urticaria
- Skin Diseases, Vascular
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Skin and Connective Tissue Diseases
- Angioedema
- Angioedemas, Hereditary
- Behavioral Disciplines and Activities
- Psychological Tests
- Ecological Momentary Assessment
Other Study ID Numbers
Other Study ID Numbers
- 2025-3.11/388
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hereditary Angioedema With C1 Esterase Inhibitor Deficiency
-
NCT06343779CompletedHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor [C1-INH] Deficiency | C1 Esterase Inhibitor Deficiency
-
NCT05396105Enrolling by invitationHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor [C1-INH] Deficiency | C1 Esterase Inhibitor Deficiency
-
NCT05047185CompletedHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor Deficiency | C1 Inhibitor Deficiency
-
NCT04618211CompletedHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor Deficiency | C1 Inhibitor Deficiency
-
NCT05833620Not yet recruitingHereditary Angioedema With C1 Esterase Inhibitor Deficiency
-
NCT02892682TerminatedChronic Spotaneous Urticaria, Idiopathic Non Histaminergic Angioderma, Hereditary Angioedema With C1 Inhibitor Deficiency
-
NCT03029728CompletedHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | C1 Esterase Inhibitor Deficiency | HAE | Angio Edema | C4 Deficiency | Hereditary Angioedema Type III
-
NCT07266805RecruitingAcquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
-
NCT07046806RecruitingAngioedema | C1 Inhibitor Deficiency | Hereditary Angioedema (HAE) | Bradykinin-mediated Angioedema
-
NCT06210698Not yet recruitingAngioedema | Urticaria | C1 Inhibitor Deficiency | Angioedemas, Hereditary | Mastocytosis | Indolent Systemic Mastocytosis | Systemic Mastocytoses | ACE Inhibitor-Induced Angioedema
Clinical Trials on ecological momentary assessment
-
NCT04375423CompletedEcological Momentary Assessment and Intervention
-
NCT06140498Completed
-
NCT07588516Not yet recruitingTreatment Adherence | Substance Use Disorder (SUD)
-
NCT02132481CompletedRecovery | Substance Use Disorder (SUD)
-
NCT07382336Recruiting
-
NCT06122298RecruitingGambling Addiction
-
NCT07309159Not yet recruiting
-
NCT05330104CompletedChemotherapy-induced Peripheral Neuropathy
-
NCT07135791RecruitingFatigue | Cerebral Palsy (CP) | Fatigue, Mental | Fatigue Symptom | Acquired Brain Injury Including Stroke | Fatigue Intensity
-
NCT06871345Not yet recruitingAutism Spectrum Disorder | Borderline Personality Disorder BPD | a Premenstrual Dysphoric Disorder (PMDD)